BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Celcuity Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Celcuity Inc.'s drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06190899-9093@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Revtorpyk (Gedatolisib): Phase 1/2 readout est. (NCT06190899)
DESCRIPTION:Revtorpyk (Gedatolisib)\, phase 1/2.\nStudy: Gedatolisib in Com
 bination With Darolutamide in Metastatic Castration-Resistant Prostate Can
 cer\nEstimated primary completion: January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gedatolisib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06190899
URL:https://assetmemo.bio/drug/gedatolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9093@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Revtorpyk (Gedatolisib): Phase 3 readout est. (NCT06757634)
DESCRIPTION:Revtorpyk (Gedatolisib)\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Phase 3 Study of Gedatolisib as First-Line Treatment for 
 Patients With HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA
 -2)\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gedatolisib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/gedatolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
